OMERS ADMINISTRATION Corp Acquires 17,200 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• OMERS ADMINISTRATION Corp increased its stake in NewAmsterdam Pharma by 83.9%, acquiring an additional 17,200 shares, bringing its total holdings to 37,700 shares valued at $772,000.
• Insider activity included COO Douglas F. Kling selling 51,043 shares for over $1 million, while Director James N. Topper bought 2,520 shares worth approximately $46,500.
• NewAmsterdam Pharma recently reported earnings per share of ($0.15), beating analysts' estimates, and is currently traded with a consensus price target of $41.55 following assessments from multiple brokerages.

OMERS ADMINISTRATION Corp increased its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 83.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 37,700 shares of the company's stock after purchasing an additional 17,200 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in NewAmsterdam Pharma were worth $772,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in NAMS. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $50,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after buying an additional 596 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after buying an additional 3,390 shares during the period. Avanza Fonder AB bought a new stake in NewAmsterdam Pharma in the 1st quarter valued at $127,000. Finally, Arizona State Retirement System bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter worth about $215,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price on the stock. Royal Bank Of Canada upped their target price on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Wells Fargo & Company began coverage on NewAmsterdam Pharma in a research note on Monday, August 25th. They issued an "overweight" rating and a $45.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Finally, Citigroup started coverage on NewAmsterdam Pharma in a research note on Tuesday, June 17th. They set a "buy" rating and a $42.00 target price for the company. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $41.55.

Insider Transactions at NewAmsterdam Pharma

In related news, Director James N. Topper purchased 2,520 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was acquired at an average price of $18.43 per share, with a total value of $46,443.60. Following the completion of the purchase, the director directly owned 3,024,873 shares in the company, valued at $55,748,409.39. This trade represents a 0.08% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 8,269 shares of the business's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $24.86, for a total value of $205,567.34. Following the completion of the transaction, the chief accounting officer directly owned 15,000 shares of the company's stock, valued at approximately $372,900. This trade represents a 35.54% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 12,835 shares of company stock worth $248,134 and sold 256,881 shares worth $5,445,954. 20.84% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock traded up $0.78 during mid-day trading on Thursday, hitting $25.66. 613,987 shares of the company's stock traded hands, compared to its average volume of 870,468. The firm has a 50 day simple moving average of $22.67 and a two-hundred day simple moving average of $20.47. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The stock has a market cap of $2.89 billion, a price-to-earnings ratio of -15.84 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The business had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. On average, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.